Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune disease characterized by muscle weakness, skin rashes, and systemic inflammation. While corticosteroids and immunosuppressants remain the cornerstone of therapy, a significant subset of patients develop refractory disease, experiencing recurrent relapses and accumulating disability. For these patients, autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a last-resort option, yet its molecular mechanisms of action remain poorly defined.
Varrica, R., Lentini, L. (2025). Alternative polyadenylation and splicing regulation in refractory juvenile dermatomyositis: CELF2 at the crossroads. MOLECULAR THERAPY NUCLEIC ACIDS, 36(4), 1-3 [10.1016/j.omtn.2025.102725].
Alternative polyadenylation and splicing regulation in refractory juvenile dermatomyositis: CELF2 at the crossroads
Varrica R.Primo
Writing – Review & Editing
;Lentini L.
Ultimo
Writing – Review & Editing
2025-12-09
Abstract
Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune disease characterized by muscle weakness, skin rashes, and systemic inflammation. While corticosteroids and immunosuppressants remain the cornerstone of therapy, a significant subset of patients develop refractory disease, experiencing recurrent relapses and accumulating disability. For these patients, autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a last-resort option, yet its molecular mechanisms of action remain poorly defined.| File | Dimensione | Formato | |
|---|---|---|---|
|
Varrica et al MOL THER NUCL ACID 2025.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
1.3 MB
Formato
Adobe PDF
|
1.3 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


